Pfizer’s rituximab investigational biosimilar PF-05280586 met the primary endpoint of overall response rate equivalence to rituximab-EU (MabThera) as a frontline treatment for patients diagnosed with CD20-positive follicular lymphoma, the company announced.
Do you know which molecular markers signify poor-risk disease in AML? And how about what makes AML a challenging disease to manage in older adult patients? Test your knowledge in our latest quiz.
Immunochemotherapy should remain the standard induction approach for patients with high-risk follicular lymphoma.
Which somatic mutation do most high-grade serous ovarian carcinomas harbor? And what percentage of endometrioid endometrial tumors have copy-number alterations? Test your knowledge in our latest quiz.
Is the use of bisphosphonates in patients with multiple myeloma associated with improved progression-free or overall survival? Is hypertension a risk factor for carfilzomib-related cardiopulmonary toxicities? Test your knowledge in our latest quiz.
Using gene expression profile tests like Oncotype DX to inform treatment decision-making for breast cancer is likely to be less cost-effective in community oncology practice than previous estimates had suggested.
Treatment of previously untreated follicular lymphoma with atezolizumab combined with obinutuzumab and bendamustine was associated with widespread adverse events and a treatment-related death, according to an interim analysis of a phase Ib/II cohort study.
Lenalidomide plus rituximab failed to demonstrate superiority over standard of care for follicular lymphoma in the phase III RELEVANCE trial.
Among patients with relapsed or refractory multiple myeloma, adding carfilzomib to lenalidomide and dexamethasone improves overall survival compared with lenalidomide and dexamethasone alone.
Which genetic mutation confers shorter progression-free survival in myelofibrosis patients undergoing allogeneic stem cell transplantation? And what is the only potentially curative treatment for primary myelofibrosis? Test your knowledge in our latest quiz.